Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
Key facts
- Who runs it
- Alexandria University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 75 people enrolled
- Started
- 17 Mar 2022
- Ended
- 18 Jan 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- gonadotropin releasing hormone-agonist
- Progesterone
- Record updated
- 29 January 2025
Who can take part
- Age
- 20 years to 38 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patient age ≤ 38 years
- BMI ≤ 30
- Basal follicle stimulating hormone (FSH) level ≤ 10 IU/L
- Anti-Müllerian hormone (AMH): ≤ 5 ng/ml
Who cannot take part
- Polycystic ovarian syndrome (PCOS)
- Comorbidities: Diabetes mellitus, hypertension, immune diseases
- Endometriosis
- Uterine pathology or anomaly
- Evidence of hydrosalpinx by hysterosalpingography or ultrasound
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the viability of the conceptus. Alterations in the peri-implantation environment are considered to impair perinatal outcomes in intracytoplasmic sperm injection (ICSI) therapy. GnRH-a is a new and promising modality for LPS. Regimens for using GnRH-a in LPS, including single mid-luteal bolus or the addition of a GnRH-a to progesterone supplementation, have been recently suggested. The aim of this study is to evaluate the impact of addition of mid-luteal single-dose or multiple-dose GnRH agonist to the routine luteal phase support in patients undergoing ICSI cycles using GnRH antagonist protocol.
The 3 groups in the trial
- Group 1Treatment being tested
Will receive routine LPS and additional single GnRH-a bolus, triptorelin 0.1 mg subcutaneous injection on the 6th day after oocyte retrieval.
Treatment: gonadotropin releasing hormone-agonist and Progesterone
- Group 2Treatment being tested
Will receive routine LPS and additional multiple mid-luteal GnRH-a, triptorelin 0.1 mg subcutaneous injection on the 5th, 7th and 9th days after oocyte retrieval.
Treatment: gonadotropin releasing hormone-agonist and Progesterone
- Group 3 (Control)Existing treatment, for comparison
Will receive the routine LPS without GnRH-a
Treatment: Progesterone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support on Antagonist ICSI Cycles
- Record updated
- 29 January 2025